RGNX:NASDAQREGENXBIO Inc. Analysis
Data as of 2026-08-26 - not real-time
$8.91
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $8.91, REGENXBIO Inc. shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have lost 27.5%. RSI sits at 40.4, which reads as neutral, and MACD momentum is bearish. The recent range runs from support at $7.77 up to resistance at $12.08.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 168.3% above today's level. Revenue is growing at 405.7% on a -112.6% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 114.9%, a beta of 1.99 and a maximum drawdown of 64.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to sell, carrying 5/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 168.3% above today's level. Revenue is growing at 405.7% on a -112.6% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 114.9%, a beta of 1.99 and a maximum drawdown of 64.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to sell, carrying 5/10 conviction.
Top Market Events
REGENXBIO Inc. Nasdaq: RGNX today announced positive data from long-term follow-up studies of investigational surabgene...Updated Aug 3, 2026 0 ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. Nasdaq: RGNX today announced that it...REGENXBIO Inc. Nasdaq: RGNX today announced the pricing of an underwritten public offering of 10,003,889 shares of its...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Trading below the 200-day average of 10.41
- MACD momentum is negative
- 30-day price change of -27.5%
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- Trading below the 200-day average of 10.41
- Analyst targets imply +168.3% versus the current price
- 30-day volatility of 114.9%
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- Negative profit margin of -112.6%
- Analyst targets imply +168.3% versus the current price
- Negative return on equity of -137.6%
Key Metrics & Analysis
Financial Health
Revenue Growth405.70%
Profit Margin-112.58%
P/E Ratio-3.0
ROE-137.63%
ROA-21.20%
Debt/Equity349.00
P/B Ratio6.7
Op. Cash Flow$-246674000
Free Cash Flow$-184263504
Industry P/E31.2
Technical Analysis
TrendNeutral
RSI40.4
Support$7.77
Resistance$12.08
MA 20$10.44
MA 50$10.83
MA 200$10.41
MACDBearish
VolumeIncreasing
Fear & Greed Index93.84
Valuation
Target Price$23.91
Upside/Downside168.34%
GradeFair
TypeGrowth
Risk Assessment
Beta1.99
Volatility114.88%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.